SAN DIEGO, CA, June 16, 2008 -- VaxInnate Corporation announced today that it will discuss its novel proprietary technology for producing seasonal and pandemic influenza vaccines during BIO 2008 here this week.
VaxInnate will participate in the following three BIO 2008 panel discussions:
On Tuesday, June 17th
- "Influenza Research and Surveillance: Preparing for the Next Pandemic,"
8:15-9:45 am in Room 29A – including Robert Becker, PhD, MBA, VaxInnate's Vice President of Business Development
On Thursday, June 19th
- "Vaccine Renaissance,"
8:30-10:00 am, Room 29A – including Dr. Robert Becker - "Moore's Law for Biomanufacturing: Innovation in a Maturing Biologicals Industry,"
4:00 - 5:30 pm, Room 29B – including Edward Arcuri, PhD, VaxInnate's Chief of Operations (COO)
VaxInnate's Approach
VaxInnate's novel technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of influenza vaccines.
VaxInnate's approach to developing and producing influenza vaccines is based upon a proprietary combination of toll-like receptor (TLR) mediated immune enhancement and recombinant bacterial production of vaccine antigen. This proprietary technology could significantly reduce the time required to produce supplies of influenza vaccine sufficient to meet national and even global needs.
VaxInnate's use of bacterial expression for production of influenza vaccines does not require costly expansion of manufacturing capacity, as do other influenza vaccine products. Due to its efficiency and transferability, VaxInnate's flu vaccine could instead be produced in existing biotechnology facilities that have microbial production capacity.
No other vaccine technology in use or in development today has these same potential capabilities.
Results of a Phase I study of VaxInnate's M2e universal vaccine candidate will be available this summer. The company plans to present the study data at a major scientific conference later this year and publish the data in a peer-reviewed journal.
The Phase I study was supported by a $9.5 million grant awarded to the University of Texas Medical Branch (UTMB) by the Bill & Melinda Gates Foundation for better control of influenza epidemics in the developing world.
About VaxInnate
VaxInnate is a privately-held biotechnology company located in Cranbury, NJ and New Haven, CT that is pioneering breakthrough technology for use in developing novel, proprietary vaccines for seasonal and pandemic influenza. This novel technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of influenza vaccines.
In addition to the M2e universal vaccine candidate in clinical development, clinical trials for hemagglutinin (HA)-based seasonal and pandemic influenza vaccine candidates will begin this year.
VaxInnate's technology platform is also being investigated for development of vaccines for other diseases. For more information about VaxInnate, please visit http://www.vaxinnate.com.